Anthropy 2022

October 31, 2022 AutoBot 0

Between the 2nd and 4th November, a veritable who’s who of British industry will gather at the Eden Project in Boldeva, Cornwall for Anthropy 2022, […]

No Image

FDA confirms amoxicillin shortage

October 31, 2022 AutoBot 0

The FDA listed 23 amoxicillin products on its current drug shortages webpage Oct. 28, confirming earlier reports from the American Society of Health-System Pharmacists. 

No Image

New tentative approval for Amneal Pharms drug saxagliptin

October 31, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

October 31, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

October 30, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

October 30, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

October 29, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

October 29, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]